The pharmaceutical industry's increasing focus on niche oncological markets has brought mucinous cystic neoplasms (MCNs) into sharp commercial focus. These rare pancreatic and ovarian tumors, while representing a small patient population, offer substantial revenue potential for companies willing to invest in specialized therapeutic development. The convergence of improved...